Details der Publikation - Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis.The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally.This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year.All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines.Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10–80% in the remaining 5 countries).The drug-resistance pattern of the patients was severe (<30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3−7) in the overall cohort and 6 (4−8) among patients with a final outcome).For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13−23) (in days 553 (385–678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30−90) days for the whole cohort and 60 (30−100) for patients with a final outcome and, respectively, of 55 (30−90) and 60 (30−90) days for culture conversion.Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up..

Medienart:	E-Artikel

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	Zur Gesamtaufnahme - volume:27
Enthalten in:	Pulmonology - 27(2021), 5, Seite 403-412

Sprache:	Englisch

Beteiligte Personen:	S. Koirala [VerfasserIn] S. Borisov [VerfasserIn] E. Danila [VerfasserIn] A. Mariandyshev [VerfasserIn] B. Shrestha [VerfasserIn] N. Lukhele [VerfasserIn] M. Dalcolmo [VerfasserIn] S.R. Shakya [VerfasserIn] S. Miliauskas [VerfasserIn] L. Kuksa [VerfasserIn] S. Manga [VerfasserIn] A. Aleksa [VerfasserIn] J.T. Denholm [VerfasserIn] H.B. Khadka [VerfasserIn] A. Skrahina [VerfasserIn] S. Diktanas [VerfasserIn] M. Ferrarese [VerfasserIn] J. Bruchfeld [VerfasserIn] A. Koleva [VerfasserIn] A. Piubello [VerfasserIn] G.S. Koirala [VerfasserIn] Z.F. Udwadia [VerfasserIn] D.J. Palmero [VerfasserIn] M. Munoz-Torrico [VerfasserIn] R. GC [VerfasserIn] G. Gualano [VerfasserIn] V.I. Grecu [VerfasserIn] I. Motta [VerfasserIn] A. Papavasileiou [VerfasserIn] Y. Li [VerfasserIn] W. Hoefsloot [VerfasserIn] H. Kunst [VerfasserIn] J. Mazza-Stalder [VerfasserIn] M.-C. Payen [VerfasserIn] O.W. Akkerman [VerfasserIn] E. Bernal [VerfasserIn] V. Manfrin [VerfasserIn] A. Matteelli [VerfasserIn] H. Mustafa Hamdan [VerfasserIn] M. Nieto Marcos [VerfasserIn] J. Cadiñanos Loidi [VerfasserIn] J.J. Cebrian Gallardo [VerfasserIn] R. Duarte [VerfasserIn] N. Escobar Salinas [VerfasserIn] R. Gomez Rosso [VerfasserIn] R. Laniado-Laborín [VerfasserIn] E. Martínez Robles [VerfasserIn] S. Quirós Fernandez [VerfasserIn] A. Rendon [VerfasserIn] I. Solovic [VerfasserIn] M. Tadolini [VerfasserIn] P. Viggiani [VerfasserIn] E. Belilovski [VerfasserIn] M.J. Boeree [VerfasserIn] Q. Cai [VerfasserIn] E. Davidavičienė [VerfasserIn] L.D. Forsman [VerfasserIn] J. De Los Rios [VerfasserIn] J. Drakšienė [VerfasserIn] A. Duga [VerfasserIn] S.E. Elamin [VerfasserIn] A. Filippov [VerfasserIn] A. Garcia [VerfasserIn] I. Gaudiesiute [VerfasserIn] B. Gavazova [VerfasserIn] R. Gayoso [VerfasserIn] V. Gruslys [VerfasserIn] J. Jonsson [VerfasserIn] E. Khimova [VerfasserIn] G. Madonsela [VerfasserIn] C. Magis-Escurra [VerfasserIn] V. Marchese [VerfasserIn] M. Matei [VerfasserIn] C. Moschos [VerfasserIn] B. Nakčerienė [VerfasserIn] L. Nicod [VerfasserIn] F. Palmieri [VerfasserIn] A. Pontarelli [VerfasserIn] A. Šmite [VerfasserIn] M.B. Souleymane [VerfasserIn] M. Vescovo [VerfasserIn] R. Zablockis [VerfasserIn] D. Zhurkin [VerfasserIn] J.-W. Alffenaar [VerfasserIn] J.A. Caminero [VerfasserIn] L.R. Codecasa [VerfasserIn] J.-M. García-García [VerfasserIn] S. Esposito [VerfasserIn] L. Saderi [VerfasserIn] A. Spanevello [VerfasserIn] D. Visca [VerfasserIn] S. Tiberi [VerfasserIn] E. Pontali [VerfasserIn] R. Centis [VerfasserIn] L. D'Ambrosio [VerfasserIn] M. van den Boom [VerfasserIn] G. Sotgiu [VerfasserIn] G.B. Migliori [VerfasserIn]

Links:	doi.org [kostenfrei] doaj.org [kostenfrei] www.sciencedirect.com [kostenfrei] Journal toc [kostenfrei]

Themen:	Bedaquiline Delamanid Diseases of the respiratory system MDR-TB Prevention of TB sequelae Treatment outcomes Tuberculosis

doi:	10.1016/j.pulmoe.2021.02.006

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	DOAJ060367482

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ060367482
003	DE-627
005	20230502155659.0
007	cr uuu---uuuuu
008	230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.pulmoe.2021.02.006 \|2 doi
035			\|a (DE-627)DOAJ060367482
035			\|a (DE-599)DOAJ79e172ec72c9400c9c19243af6bbaddf
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC705-779
100	0		\|a S. Koirala \|e verfasserin \|4 aut
245	1	0	\|a Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis.The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally.This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year.All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines.Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10–80% in the remaining 5 countries).The drug-resistance pattern of the patients was severe (<30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3−7) in the overall cohort and 6 (4−8) among patients with a final outcome).For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13−23) (in days 553 (385–678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30−90) days for the whole cohort and 60 (30−100) for patients with a final outcome and, respectively, of 55 (30−90) and 60 (30−90) days for culture conversion.Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.
650		4	\|a Tuberculosis
650		4	\|a MDR-TB
650		4	\|a Delamanid
650		4	\|a Bedaquiline
650		4	\|a Treatment outcomes
650		4	\|a Prevention of TB sequelae
653		0	\|a Diseases of the respiratory system
700	0		\|a S. Borisov \|e verfasserin \|4 aut
700	0		\|a E. Danila \|e verfasserin \|4 aut
700	0		\|a A. Mariandyshev \|e verfasserin \|4 aut
700	0		\|a B. Shrestha \|e verfasserin \|4 aut
700	0		\|a N. Lukhele \|e verfasserin \|4 aut
700	0		\|a M. Dalcolmo \|e verfasserin \|4 aut
700	0		\|a S.R. Shakya \|e verfasserin \|4 aut
700	0		\|a S. Miliauskas \|e verfasserin \|4 aut
700	0		\|a L. Kuksa \|e verfasserin \|4 aut
700	0		\|a S. Manga \|e verfasserin \|4 aut
700	0		\|a A. Aleksa \|e verfasserin \|4 aut
700	0		\|a J.T. Denholm \|e verfasserin \|4 aut
700	0		\|a H.B. Khadka \|e verfasserin \|4 aut
700	0		\|a A. Skrahina \|e verfasserin \|4 aut
700	0		\|a S. Diktanas \|e verfasserin \|4 aut
700	0		\|a M. Ferrarese \|e verfasserin \|4 aut
700	0		\|a J. Bruchfeld \|e verfasserin \|4 aut
700	0		\|a A. Koleva \|e verfasserin \|4 aut
700	0		\|a A. Piubello \|e verfasserin \|4 aut
700	0		\|a G.S. Koirala \|e verfasserin \|4 aut
700	0		\|a Z.F. Udwadia \|e verfasserin \|4 aut
700	0		\|a D.J. Palmero \|e verfasserin \|4 aut
700	0		\|a M. Munoz-Torrico \|e verfasserin \|4 aut
700	0		\|a R. GC \|e verfasserin \|4 aut
700	0		\|a G. Gualano \|e verfasserin \|4 aut
700	0		\|a V.I. Grecu \|e verfasserin \|4 aut
700	0		\|a I. Motta \|e verfasserin \|4 aut
700	0		\|a A. Papavasileiou \|e verfasserin \|4 aut
700	0		\|a Y. Li \|e verfasserin \|4 aut
700	0		\|a W. Hoefsloot \|e verfasserin \|4 aut
700	0		\|a H. Kunst \|e verfasserin \|4 aut
700	0		\|a J. Mazza-Stalder \|e verfasserin \|4 aut
700	0		\|a M.-C. Payen \|e verfasserin \|4 aut
700	0		\|a O.W. Akkerman \|e verfasserin \|4 aut
700	0		\|a E. Bernal \|e verfasserin \|4 aut
700	0		\|a V. Manfrin \|e verfasserin \|4 aut
700	0		\|a A. Matteelli \|e verfasserin \|4 aut
700	0		\|a H. Mustafa Hamdan \|e verfasserin \|4 aut
700	0		\|a M. Nieto Marcos \|e verfasserin \|4 aut
700	0		\|a J. Cadiñanos Loidi \|e verfasserin \|4 aut
700	0		\|a J.J. Cebrian Gallardo \|e verfasserin \|4 aut
700	0		\|a R. Duarte \|e verfasserin \|4 aut
700	0		\|a N. Escobar Salinas \|e verfasserin \|4 aut
700	0		\|a R. Gomez Rosso \|e verfasserin \|4 aut
700	0		\|a R. Laniado-Laborín \|e verfasserin \|4 aut
700	0		\|a E. Martínez Robles \|e verfasserin \|4 aut
700	0		\|a S. Quirós Fernandez \|e verfasserin \|4 aut
700	0		\|a A. Rendon \|e verfasserin \|4 aut
700	0		\|a I. Solovic \|e verfasserin \|4 aut
700	0		\|a M. Tadolini \|e verfasserin \|4 aut
700	0		\|a P. Viggiani \|e verfasserin \|4 aut
700	0		\|a E. Belilovski \|e verfasserin \|4 aut
700	0		\|a M.J. Boeree \|e verfasserin \|4 aut
700	0		\|a Q. Cai \|e verfasserin \|4 aut
700	0		\|a E. Davidavičienė \|e verfasserin \|4 aut
700	0		\|a L.D. Forsman \|e verfasserin \|4 aut
700	0		\|a J. De Los Rios \|e verfasserin \|4 aut
700	0		\|a J. Drakšienė \|e verfasserin \|4 aut
700	0		\|a A. Duga \|e verfasserin \|4 aut
700	0		\|a S.E. Elamin \|e verfasserin \|4 aut
700	0		\|a A. Filippov \|e verfasserin \|4 aut
700	0		\|a A. Garcia \|e verfasserin \|4 aut
700	0		\|a I. Gaudiesiute \|e verfasserin \|4 aut
700	0		\|a B. Gavazova \|e verfasserin \|4 aut
700	0		\|a R. Gayoso \|e verfasserin \|4 aut
700	0		\|a V. Gruslys \|e verfasserin \|4 aut
700	0		\|a J. Jonsson \|e verfasserin \|4 aut
700	0		\|a E. Khimova \|e verfasserin \|4 aut
700	0		\|a G. Madonsela \|e verfasserin \|4 aut
700	0		\|a C. Magis-Escurra \|e verfasserin \|4 aut
700	0		\|a V. Marchese \|e verfasserin \|4 aut
700	0		\|a M. Matei \|e verfasserin \|4 aut
700	0		\|a C. Moschos \|e verfasserin \|4 aut
700	0		\|a B. Nakčerienė \|e verfasserin \|4 aut
700	0		\|a L. Nicod \|e verfasserin \|4 aut
700	0		\|a F. Palmieri \|e verfasserin \|4 aut
700	0		\|a A. Pontarelli \|e verfasserin \|4 aut
700	0		\|a A. Šmite \|e verfasserin \|4 aut
700	0		\|a M.B. Souleymane \|e verfasserin \|4 aut
700	0		\|a M. Vescovo \|e verfasserin \|4 aut
700	0		\|a R. Zablockis \|e verfasserin \|4 aut
700	0		\|a D. Zhurkin \|e verfasserin \|4 aut
700	0		\|a J.-W. Alffenaar \|e verfasserin \|4 aut
700	0		\|a J.A. Caminero \|e verfasserin \|4 aut
700	0		\|a L.R. Codecasa \|e verfasserin \|4 aut
700	0		\|a J.-M. García-García \|e verfasserin \|4 aut
700	0		\|a S. Esposito \|e verfasserin \|4 aut
700	0		\|a L. Saderi \|e verfasserin \|4 aut
700	0		\|a A. Spanevello \|e verfasserin \|4 aut
700	0		\|a D. Visca \|e verfasserin \|4 aut
700	0		\|a S. Tiberi \|e verfasserin \|4 aut
700	0		\|a E. Pontali \|e verfasserin \|4 aut
700	0		\|a R. Centis \|e verfasserin \|4 aut
700	0		\|a L. D'Ambrosio \|e verfasserin \|4 aut
700	0		\|a M. van den Boom \|e verfasserin \|4 aut
700	0		\|a G. Sotgiu \|e verfasserin \|4 aut
700	0		\|a G.B. Migliori \|e verfasserin \|4 aut
773	0	8	\|i In \|t Pulmonology \|d Elsevier España, 2018 \|g 27(2021), 5, Seite 403-412 \|w (DE-627)DOAJ00000488X \|x 25310437 \|7 nnns
773	1	8	\|g volume:27 \|g year:2021 \|g number:5 \|g pages:403-412
856	4	0	\|u https://doi.org/10.1016/j.pulmoe.2021.02.006 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/79e172ec72c9400c9c19243af6bbaddf \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S2531043721000532 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2531-0437 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|d 27 \|j 2021 \|e 5 \|h 403-412

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände